ESMO World Congress on Gastrointestinal Cancer 2016

Oncology Meeting Resources

29 Jun - 02 Jul 2016, Barcelona, Spain

World GI 2016 Square Image

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts from the ESMO World GI 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.





Format available

http://oncologypro.esmo.org/Meeting-Resourc...ody-Mass-Index-in-colorectal-cancer-patients

Depletion of skeletal muscle (sarcopenia) and, hence, of overall Lean Body Mass (LBM) has been associated with poor performance status, chemotherapy toxicity, and shortened survival in cancer patients,...

Date: 29 Jun 2016
Presenter: V. Alivizatos
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...uodenum-case-series-from-North-Eastern-India

Duodenal neuroendocrine tumors (DNET) are rare tumours. We audited the clinic-pathological, radiological and endoscopic features of patients with DNET.

Date: 29 Jun 2016
Presenter: T. Chawla
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...nd-clinical-aspects-of-the-canal-anal-cancer

Cancers of the anal canal represent 1.5% of digestive cancers [1]. They predominate in women (sex ratio of 4 in France) and two thirds of patients over 65 years. The incidence is increasing and the age at diagnosis decreased.

Date: 29 Jun 2016
Presenter: A. Zemmour
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...nt-Chemo-radiotherapy-an-institutional-study

Background: Gall bladder carcinoma (GBC) is considered the fifth most common one of the most aggressive gastro intestinal tract malignancies. Over the years surgical resection has been considered the only curative treatment of these tumours.

Date: 29 Jun 2016
Presenter: S. Saugat
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ld-GI-2016/Metastatic-gastric-adenocarcinoma

Gastric adenocarcinoma is the fourth most common cancer worldwide (7.8% of cancers) but the second leading cause of cancer death (9.7% of cancer deaths). The 5-year survival for advanced/metastatic...

Date: 29 Jun 2016
Presenter: M. Belmadi
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ministration-interval-in-cetuximab-treatment

HGCSG0902 is the multicenter phase II study to investigate the safety and efficacy of irinotecan, S-1 (IRIS) plus cetuximab as second line treatment in patients with KRAS exon2 wild type mCRC.

Date: 29 Jun 2016
Presenter: S. Yuki
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...nd-line-therapy-in-pancreatic-adenocarcinoma

Advanced pancreatic cancer patients receiving FOLFORINOX or gemzar/abraxane as first-line treatment have no standard second-line treatment option following progression.

Date: 29 Jun 2016
Presenter: S. Temraz
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...olorectal-Liver-Metastases-Systematic-Review

Analysis of overall survival (OS) in phase III trials with low progressive malignancies is an issue hardly addressed since it demands large samples, great cost and longer follow-up.

Date: 29 Jun 2016
Presenter: R. Araujo
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...e-locally-advanced-pancreatic-adenocarcinoma

Neo-adjuvant therapy with FOLFIRINOX in patients with locally advanced/borderline resectable pancreatic cancer has the potential to down-stage tumors enabling surgical resection.

Date: 29 Jun 2016
Presenter: S. Temraz
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...an-exploratory-retrospective-pooled-analysis

Biologic therapies such as epidermal growth factor receptor inhibitors (EGFRi) and vascular endothelial growth factor inhibitors (VEGFi) improve clinical outcomes of patients with RAS WT mCRC when added...

Date: 29 Jun 2016
Presenter: A. Sobrero
Resources: Abstract